Autoimmune Gastritis
Conditions
Interventions
Prospective Study - Analysis of Changes in Gastric Microbiota in Autoimmune Gastritis - Experimental Group:Suffering from autoimmune gastritis
Prospective Study - Analysis of Changes in Gastric Microbiota in Autoimmune Gastritis - Control Group:None. Controls were endoscopically diagnosed with chronic non-atrophic gastritis and negative 13C-
A retrospective study - Clinical characterization of autoimmune gastritis:Suffering from autoimmune gastritis
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Part 1: Patients diagnosed with AIG at the Army Characteristic Medical Center between January 2020 and June 2024, with an estimated sample size of around 100 cases. (Diagnostic criteria: ? Obvious retrograde atrophy phenomenon is found under endoscopy (the degree of atrophy of the gastric antrum is weaker than that of the gastric body and fundus); ? The results of histology (pathological biopsy reveals atrophy of the gastric body or fundus, accompanied by neuroendocrine cell proliferation and loss of parietal cells) or serology (positive for anti parietal cell antibodies or anti intrinsic factor antibodies) are either positive. Part 2: 1. Age: Adults, 18-80 years old, male or female not limited; 2. Observation group: Diagnosed with AIG (diagnostic criteria: ? Significant retrograde atrophy observed under endoscopy (the degree of atrophy of the gastric antrum is weaker than that of the gastric body and fundus); ? The results of histology (pathological biopsy reveals atrophy of the gastric body or fundus, accompanied by neuroendocrine cell proliferation and loss of parietal cells) or serology (positive for anti parietal cell antibodies or anti intrinsic factor antibodies) are either positive; 3. Control group: Diagnosed with chronic non atrophic gastritis under endoscopy, with negative 13C urea breath test.
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria for the experimental group: (1) the presence of other serious diseases that affect the evaluation of this study, such as severe liver, kidney, cardiovascular disease, etc; (2) Individuals who are unable to undergo endoscopic examination; (3) Patients with coagulation dysfunction, long-term use of anticoagulant or antiplatelet drugs, or other reasons that prevent gastric mucosal biopsy surgery; (4) Pregnant or lactating women; (5) Those who cannot sign the informed consent form; (6) History of using PPI, P-CAB, bismuth agents, antibiotics, and microbial preparations within one month; (7) History of subtotal gastrectomy, active peptic ulcer, reflux esophagitis, esophageal ulcer, etc; 2. Exclusion criteria for the control group: (1) the presence of other serious diseases that affect the evaluation of this study, such as severe liver, kidney, cardiovascular disease, etc; (2) Merge other gastrointestinal diseases such as peptic ulcers, polyps, inflammatory bowel disease, malignant tumors, etc; (3) Individuals who are unable to undergo endoscopic examination; (4) Patients with coagulation dysfunction, long-term use of anticoagulant or antiplatelet drugs, or other reasons that prevent gastric mucosal biopsy surgery; (5) Pregnant or lactating women; (6) Those who cannot sign the informed consent form; (7) History of using PPI, P-CAB, bismuth agents, antibiotics, and microbial preparations within one month; (8) History of HP eradication; (9) Positive urea breath test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of gastric mucosal flora; | — |
Countries
China
Contacts
Public ContactLan Chunhui
Army Medical Center of PLA
Outcome results
None listed